目的 研究吉非替尼对人肺癌细胞A549增殖及凋亡的影响，并探讨其作用的分子机制。 方法 采用MTT［3-(4,5-二甲基噻唑-2)-2，5-二苯基四氮唑溴盐］比色法观察吉非替尼对人肺癌细胞A549生长增殖的影响；Annexin Ⅴ-FITC/PI双染法检测吉非替尼对人肺癌细胞A549凋亡的影响。Western blot法检测信号转导和转录激活因子3（signal transducer and activator of transcription 3, STAT 3）表达的改变。 结果 吉非替尼作用后，MTT检测显示A549细胞增殖活性明显被抑制，最高细胞生长抑制率为（80.20±0.45）%（ P ＜0.05）；Annexin Ⅴ-FITC/PI双染法检测结果显示细胞凋亡率为（41.39±1.74）%，明显升高（ P ＜0.05）。Western blotting法检测结果显示STAT 3表达明显下降。 结论 吉非替尼可明显抑制人肺癌细胞A549的增殖，并且诱导其早期凋亡，该作用可能与吉非替尼处理后A549细胞中STAT 3表达的下调有关。
Abstract
Objective To investigate the effect of gefitinib on the growth of human lung cancer cell line A549 and its molecular machenism. Methods The growth suppressing effect of gefitinib on A549 was quantified by MTT assay. Apoptosis was assayed with annexinⅤ-FITC/PI doubled stained flow cytometry. Western blotting assay was adopted to identify the expression of STAT3. Results After treatment with gefitinib, MTT showed that cell proliferation was inhibited, and the highest inhibitory rate was (80.20±0.45)% ( P ＜0.05). AnnexinⅤ-FITC/PI doubled stained flow cytometry showed that the cell apoptosis rate was (41.39±1.74)%, rising remarkably ( P ＜0.05). Western blotting showed significant decline of expression of STAT 3. Conclusions Gefitinib can significantly inhibit the growth of human lung cancer cell line A549 and induce early apoptosis. The effect may be due to the down-regulation of STAT 3 expression.
关键词
吉非替尼 /
肺癌 /
增殖 /
凋亡 /
信号转导和转录激活因子
Key words
gefitinib /
lung cancer /
proliferation /
apoptosis /
signal transducer and activator of transcription 3
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
［1］Harichand-HerdtS,RamalingamSS.Targetedtherapyforthetreatmentofnon-smallcelllungcancer:focusoninhibitionofepidermalgrowthfactorreceptor［J］.SeminThoracCardiovascSurg,2008,20(3):217-223.
［2］BansalN,YendluriV,WenhamRM.Themolecularbiologyofendometrialcancersandtheimplicationsforpathogenesis,classification,andtargetedtherapies［J］.CancerControl,2009,16(1):8-13.
［3］JinQ,EstevaFJ.Cross-talkbetweentheErbB/HERfamilyandthetypeIinsulin-likegrowthfactorreceptorsignalingpathwayinbreastcancer［J］.JMammaryGlandBiolNeoplasia,2008,13(4):485-498.
［4］SawyersC.Targetedcancertherapy［J］.Nature,2004,432(70):294-297.
［5］SalomonDS,BrandtR,CiardielloF,etal.Epidermaigrowthfactor-relatedpeptidesandtheirreceptorsinhumanmalignancies［J］.CritRevOncolHematol,1995,19(3):183-232.
［6］〖KG-0.7mm〗WestHJ.Noveltargetedagentsforlungcancer［J］.ClinLungCancer,2009,10(1):41-46.
［7］〖KG-0.7mm〗JoyAA,ButtsCA.Extendingoutcomes:epidermalgrowthfactorreceptor-targetedmonoclonalantibodiesinnon-small-celllungcancer［J］.ClinLungCancer,2009,10(1):24-29.
［8］PakkalaS,RamalingamSS.Combinedinhibitionofvescularendothelialgrowthfactorandepidermalgrowthfactorsignalinginnon-small-celllungcancertherapy［J］.ClinLungCancer,2009,10(1):17-23.
［9］PennellNA,LynchTJ.CombinedinhibitionoftheVEGFRandEGFRsignalingpathwaysinthetreatmentofNSCLC［J］.Oncologist,2009,14(4):399-411.
［10］〖JP4〗BlackledgeG,AverbuchS.Genifitinib(‘Iressa’,ZD1839)andnewepidermalgrowthfactorreceptorinhibitors［J］.BrJCancer,2004,90(3):566-572.
［11］〖JP3〗LinCC,YangCH.Epidermalgrowthfactorreceptortyrosinekinaseinhibitorsinelderlyorpoorperformancestatuspatientswithadvancednon-smallcelllungcancer［J］.TargetOncol,2009,4(1):37-44.
［12］〖JP3〗LiJ,LiY,FengZ,etal.Anti-tumoractivityofanovelEGFRtyrosinekinaseinhibitoragainsthumanNSCLCinvitroandinvivo［J］.CancerLett,2009,279(2):213-220.
PDF(529 KB)
